UBS Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)

July 11, 2025 9:07 AM EDT Send to a Friend
UBS analyst Trung Huynh reiterated a Neutral rating and $52.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login